150

Blink Charging Donates EV Chargers to Tennessee Non-Profit, Socially Equal Energy Efficient Development, to Provide Charging Access to Low Income Families

Retrieved on: 
Wednesday, October 26, 2022

Miami, Fla., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Blink Charging Co. (Nasdaq: BLNK, BLNKW) (“Blink” or the “Company”), a leading owner and operator of electric vehicle (EV) charging equipment and services, today announced a donation of 10 Blink HQ 150 Level 2 chargers to the Tennessee Socially Equal Energy Efficient Development (SEEED), a non-profit that seeks to serve the young adults and largely marginalized community members in the greater Knoxville area. These deployments are the first Blink chargers distributed to SEEED as part of their commitment to ensure equitable access to electric vehicle charging.

Key Points: 
  • These deployments are the first Blink chargers distributed to SEEED as part of their commitment to ensure equitable access to electric vehicle charging.
  • This donation from Blink helps to provide residents of East Knoxville with access to EV charging and supports SEEEDs vision of an inclusive and sustainable future.
  • Blinks principal line of products and services include the Blink EV charging network (Blink Network), EV charging equipment, EV charging services, and the products and services of recent acquisitions, including SemaConnect, Blue Corner and BlueLA.
  • Except as required by federal securities law, Blink Charging undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

ERYTECH Announces Receipt of Nasdaq Notice

Retrieved on: 
Thursday, October 13, 2022

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the applicable grace period to regain compliance is 180 days, or until April 5, 2023.

Key Points: 
  • Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the applicable grace period to regain compliance is 180 days, or until April 5, 2023.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Provides Regulatory Update

Retrieved on: 
Wednesday, August 24, 2022

We are obviously disappointed to stop the process of seeking approval for Graspa in ALL after all the work done and clinical promise observed in this indication, said Gil Beyen, Chief Executive Officer of ERYTECH.

Key Points: 
  • We are obviously disappointed to stop the process of seeking approval for Graspa in ALL after all the work done and clinical promise observed in this indication, said Gil Beyen, Chief Executive Officer of ERYTECH.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP).
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

Retrieved on: 
Tuesday, May 24, 2022

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022

Key Points: 
  • ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
    Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 24, 2022.
  • ERYTECHs shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Htel Intercontinental Paris Le Grand, 2 rue Scribe, 75009 Paris (FRANCE).
  • Shareholders have access to the preparatory and information documents for the Shareholders Meeting as provided for by law and the regulations.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022

The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards.

Key Points: 
  • The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards.
  • For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference website https://hcwevents.com/globalconference/ .
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Provides Business and Financial Update for the First Quarter of 2022

Retrieved on: 
Thursday, May 12, 2022

As of March 31, 2022, ERYTECH had cash and cash equivalents totaling 25.1 million (approximately $27.9 million), compared with 33.7 million as of December 31, 2021.

Key Points: 
  • As of March 31, 2022, ERYTECH had cash and cash equivalents totaling 25.1 million (approximately $27.9 million), compared with 33.7 million as of December 31, 2021.
  • The company does not plan to draw any further OCABSA tranche until the expiration of the financing facility in June 2022.
  • ERYTECH management will hold a conference call and webcast on Friday, May 13, 2022, at 8:30am ET / 2:30 pm CEST on the business highlights and financial results for the quarter ended March 31, 2022.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar

Retrieved on: 
Thursday, April 28, 2022

These documents can be accessed on the Investors section of the Companys corporate website ( www.erytech.com ).

Key Points: 
  • These documents can be accessed on the Investors section of the Companys corporate website ( www.erytech.com ).
  • In addition, the Universal Registration Document is available on the website of the AMF ( www.amf-france.org ) and the Annual Report on Form 20-F is also available on the website of the SEC ( www.sec.gov ).
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent

Retrieved on: 
Monday, April 25, 2022

Under the terms of an asset purchase agreement between ERYTECH and Catalent (the APA), Catalent agreed to acquire ERYTECHs state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of $44.5 million.

Key Points: 
  • Under the terms of an asset purchase agreement between ERYTECH and Catalent (the APA), Catalent agreed to acquire ERYTECHs state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of $44.5 million.
  • ERYTECHs Princeton facility is a 30,900 sqft cutting edge manufacturing facility, designed with the flexibility to expand to support various cell therapy production requirements and capacities.
  • ERYTECH will retain its manufacturing site in Lyon, France and its expertise and capabilities in manufacturing process science to continue innovating in cell therapy manufacturing.
  • The parties will also enter into a long-term supply agreement for the manufacturing and supply of the lead product candidate eryaspase (GRASPA) by Catalent to ERYTECH.

ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

Retrieved on: 
Wednesday, April 6, 2022

The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.

Key Points: 
  • The Phase 2 NOR-GRASPALL-2016 trial evaluated the safety and pharmacological profile of eryaspase in ALL patients who had previously experienced hypersensitivity reactions to pegylated asparaginase therapy.
  • Eryaspase demonstrated sustained asparaginase enzyme activity above the threshold of >100 U/L at trough levels 14 days after first infusion in 92.5% of patients.
  • The Principal Investigator, Dr. Birgitte Klug Albertsen, Associate Professor at Aarhus University Hospital, Denmark, commented, "I am grateful that the editors of the British Journal of Haematology selected our study for publication.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society

Retrieved on: 
Monday, April 4, 2022

Oral presentation: Evaluation of production methods, characterization and biological activity of RBC-derived extracellular vesicles (RBCEVs) containing active molecules.

Key Points: 
  • Oral presentation: Evaluation of production methods, characterization and biological activity of RBC-derived extracellular vesicles (RBCEVs) containing active molecules.
  • Vesiculation of RBCs that have already been loaded with active therapeutic compounds utilizing the ERYCAPS process, entails the potential of producing cargo-loaded RBC-derived extracellular vesicles for the development of novel therapeutic approaches.
  • ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.